WilmerHale Advises Coherus Oncology on its Clinical Supply Agreement with Johnson & Johnson to Evaluate Tagmokitug in Combination with Pasritamig

WilmerHale Advises Coherus Oncology on its Clinical Supply Agreement with Johnson & Johnson to Evaluate Tagmokitug in Combination with Pasritamig

Client News

Related Solutions

Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.

Coherus Oncology, Inc. (NASDAQ: CHRS) entered into a clinical supply agreement with Johnson & Johnson to evaluate tagmokitug (CHS-114), Coherus Oncology’s investigational anti-CCR8 cytolytic monoclonal antibody, in combination with pasritamig, a T-cell engaging bispecific antibody, in a Phase 1b clinical study in patients with metastatic castration-resistant prostate cancer (mCRPC). 

WilmerHale advised Coherus Oncology in connection with the agreement.

Under the terms of the clinical supply agreement, Johnson & Johnson will provide pasritamig to Coherus, which will be the sponsor of the Phase 1b clinical trial. Johnson & Johnson and Coherus each retain all commercial rights to their respective compounds, including as monotherapy or as combination treatments.

The WilmerHale team was led by Jekkie Kim and included Mizuna Sekine.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link. (The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel